Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

KATHERINE L NEUBAUER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1720349541
CMS profile
1010593
Location
WEST FARGO, ND

General Payments · PY2019–2024

$134,213.81

  • Reported across 58 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$34,319.29

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $34,295.24 13
Food and Beverage $24.05 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $34,295.24 13
Exact Sciences Corporation $24.05 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $475.00 1
PY2020 $18,600.00 9
PY2021 $25,800.00 11
PY2022 $34,944.00 14
PY2023 $20,075.52 9
PY2024 $34,319.29 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Exact Sciences Corporation $24.05 05/06/2024 Food and Beverage Undisputed 01/23/2026 1114807323 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 02/16/2024 Consulting Fee Undisputed 01/23/2026 1137642784 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 02/16/2024 Consulting Fee Undisputed 01/23/2026 1137642786 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 02/16/2024 Consulting Fee Undisputed 01/23/2026 1137642788 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 03/15/2024 Consulting Fee Undisputed 01/23/2026 1137642790 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137642792 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 05/17/2024 Consulting Fee Undisputed 01/23/2026 1137642794 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 06/14/2024 Consulting Fee Undisputed 01/23/2026 1137642796 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 07/24/2024 Consulting Fee Undisputed 01/23/2026 1137642798 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,235.40 08/21/2024 Consulting Fee Undisputed 01/23/2026 1137642800 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 09/18/2024 Consulting Fee Undisputed 01/23/2026 1137642802 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,941.24 10/16/2024 Consulting Fee Undisputed 01/23/2026 1137642804 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,235.40 11/15/2024 Consulting Fee Undisputed 01/23/2026 1137642806 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,588.32 12/16/2024 Consulting Fee Undisputed 01/23/2026 1137642808 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.